phrykt

Filana Therapeutics, Inc. (FLNA): who owns it and who trades it

As of Nov 12, 2026, FLNA insiders reported 6 purchases worth $997K in the last 12 months. The largest buyer was Richard Barry (CEO), with $972K. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 12, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Filana Therapeutics

From the latest filings

Overall: about as much buying as selling. Funds and famous investors mostly sold. Insiders mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns FLNA

82 funds and institutions reported FLNA shares worth $15.1M at the end of Q2 2026, about 26% of the company. The largest holder is Vanguard Capital Management LLC with 4.1%.

Funds and institutions (13F) 26%Everyone else 74%

10 largest owners, by share of the company

Vanguard Capital Management LLC4.1%
Two Sigma Investments, LP3.5%
Marshall Wace, LLP3.3%
BlackRock, Inc.3.0%
Goldman Sachs Group Inc1.4%
Geode Capital Management, LLC1.3%
D. E. Shaw & Co., Inc.1.0%
GMT Capital Corp0.9%
Renaissance Technologies LLC0.8%
Squarepoint Ops LLC0.7%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Vanguard Capital Management LLC1.97M4.09%$2.4M+2%
Two Sigma Investments, LP1.71M3.54%$2M-14%
Marshall Wace, LLP1.60M3.31%$1.9M-21%
BlackRock, Inc.1.45M3.01%$1.7M+3%
Goldman Sachs Group Inc668,7921.38%$796K+1518%
Geode Capital Management, LLC615,5101.27%$733K+3%
D. E. Shaw & Co., Inc.485,0251.00%$577K-13%
GMT Capital Corp450,1000.93%$536KNo change
Renaissance Technologies LLC389,6010.81%$464K+19%
Squarepoint Ops LLC318,3800.66%$379KNew
Vanguard Fiduciary Trust Co315,8890.65%$376K+15%
Acadian Asset Management LLC295,0590.61%$350K+4%
Susquehanna International Group, LLP292,0170.60%$348K-35%
Gsa Capital Partners LLP269,4100.56%$321K+24%
Group One Trading LLC244,0080.51%$290K-19%
State Street Corp209,1050.43%$249K-13%
Vanguard Portfolio Management LLC132,5970.27%$158K-0%
Connor, Clark & Lunn Investment Management Ltd.132,2980.27%$157K-3%
Federated Hermes, Inc.119,9520.25%$143K+4%
Northern Trust Corp114,3220.24%$136K-23%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, FLNA insiders reported $997K of open-market purchases and $0 of sales.

Purchases, 12 months
$997K
6 trades, 2 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Sep 30, 2026
Filed Oct 1, 2026

Purchases and sales by month

$356K$356KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 30, 2026Richard BarryCEOPurchase100,000$0.92$92KForm 4
Sep 29, 2026Richard BarryCEOPurchase206,813$0.90$186KForm 4
Sep 28, 2026Richard BarryCEOPurchase93,091$0.84$78.2KForm 4
Nov 24, 2025Robert Eugene Anderson JrDirectorPurchase8,600$2.90$24.9KForm 4
Nov 20, 2025Richard BarryCEOPurchase150,000$2.76$414KForm 4
Nov 19, 2025Richard BarryCEOPurchase73,385$2.75$202KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Richard BarryPresident & CEO, Director$972K–Sep 30, 2026
Robert Eugene Anderson JrDirector$24.9K–Nov 24, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

FLNA short interest

High short interest. 11.8% of FLNA shares are sold short: about 1 share in 9. Over the last 12 reports the number of shares short went down 15%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 5.68M FLNA shares were sold short, 11.8% of the shares outstanding, up 1.4% from the report before. At the average daily volume of 275,805 shares, buying them all back would take about 20.6 trading days (days to cover).

Shares short, % of all shares

11.8%May 15Oct 3014.7%

Days to cover

20.6May 15Oct 3037.4

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20265.68M11.76%+1%275,80520.6
Oct 15, 20265.60M11.60%-5%821,2846.8
Sep 30, 20265.89M12.18%-5%9.67M1.0
Sep 15, 20266.22M12.87%-1%332,69118.7
Aug 31, 20266.29M13.03%-0%192,67132.7
Aug 14, 20266.31M13.06%-2%339,86018.6
Jul 31, 20266.46M13.37%+4%311,90420.7
Jul 15, 20266.24M12.91%-4%421,85514.8
Jun 30, 20266.49M13.43%-1%320,67620.2
Jun 15, 20266.58M13.61%-4%330,05419.9
May 29, 20266.89M14.25%+3%410,19916.8
May 15, 20266.69M13.85%-2%455,97214.7

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Filana Therapeutics company events

Filana Therapeutics filed 16 reports on Form 8-K in the last 12 months, 5 of them about an important change (leadership, listing). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Oct 20, 2026AnnouncementThe United States Court of Appeals for the Fifth Circuit vacated the order of the U.S. District Court for the Western District of Texas granting class certification in the securities class action pending against Filana Therapeutics, Inc. and certain named officers and employees (together with the… Filing
  3. Sep 22, 2026AnnouncementOf this Current Report on Form 8-K. A copy of the press release is attached as Exhibit 99.1 and incorporated into this Item 7.01 by reference. Filing
  4. Sep 18, 2026ListingFilana Therapeutics, Inc. received written notice from the Nasdaq Stock Market, LLC indicating that the bid price for the Company’s common stock, for the last thirty (30) consecutive business days, had closed below the minimum $1.00 per share and, as a result, the Company is not in compliance with… Filing
  5. Jul 29, 2026ResultsReleased financial results. Filing
  6. Jun 15, 2026LeadershipAs described in Item 5.07 below, on June 11, 2026, at the 2026 Annual Meeting of Stockholders of Filana Therapeutics, Inc., the stockholders of the Company approved Amendment No. 2 to the Company’s 2018 Omnibus Incentive Plan (as amended, the “2018 Plan”). Filing
  7. May 7, 2026ResultsReleased financial results. Filing
  8. Apr 28, 2026LeadershipReported a change among its top officers or directors, or their pay. Filing
  9. Mar 12, 2026ResultsReleased financial results. Filing
  10. Mar 10, 2026RulesChanged its bylaws or articles. Filing
  11. Feb 19, 2026AnnouncementOf this Current Report on Form 8-K. A copy of the press release is attached as Exhibit 99.1 hereto and incorporated into this Item 7.01 by reference. Filing
  12. Dec 23, 2025AgreementBackground Between August 27, 2021 and October 26, 2021, four putative class action lawsuits were filed alleging violations of the federal securities laws by the Company and certain named officers. Filing
  13. Dec 22, 2025LeadershipAmended an earlier report. Reported a change among its top officers or directors, or their pay. Filing
  14. Dec 18, 2025AnnouncementFollowing previously reported communications with the U.S. Food and Drug Administration regarding Cassava Sciences, Inc.’s investigational new drug application (IND) and proposed proof-of-concept clinical trial for simufilam in tuberous sclerosis complex-related epilepsy, on December 15, 2025, the… Filing
  15. Dec 17, 2025LeadershipThe Board of Directors of Cassava Sciences, Inc. approved cash bonus awards for calendar 2025 for the Company’s named executive officers in recognition of their contributions to the Company as follows: Name Title Bonus Amount Richard J. Barry President & Chief Executive Officer $ 355,000 Eric J.… Filing
  16. Dec 3, 2025AnnouncementAs previously reported, Cassava Sciences, Inc. has submitted an investigational new drug application to the U.S. Food and Drug Administration in support of a proposed proof-of-concept clinical trial for simufilam in tuberous sclerosis complex-related epilepsy. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Filana Therapeutics financials

Famous investors that hold FLNA

1 of the 50 well-known investors we track reported holding FLNA in their latest 13F filing. The largest position is Jim Simons's, worth $197K.

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 2026222,359$197K0.0%-43%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Filana Therapeutics, Inc. (FLNA) stock

Who owns the most FLNA stock?

The largest reported owner of Filana Therapeutics, Inc. (FLNA) is Vanguard Capital Management LLC, with 4.1% of the company. In total, 82 funds and institutions reported holding FLNA at the end of Q2 2026, together about 26% of the shares. See the largest owners.

Are FLNA insiders buying or selling?

In the last 12 months, FLNA insiders reported 6 open-market purchases worth $997K and no sales. The latest trade was on Sep 30, 2026. See every trade.

What is the short interest in FLNA?

As of Oct 30, 2026, 5.68M FLNA shares were sold short, 11.8% of the shares outstanding, up 1.4% from the report before. At the average daily volume of 275,805 shares, buying them all back would take about 20.6 trading days (days to cover). See the history.

Which famous investors hold FLNA?

1 of the 50 well-known investors we track reported FLNA in their latest 13F filing, including Jim Simons. The largest position is worth $197K. See all holders.

Executive pay

Filana Therapeutics's chief executive was paid a total of $1.5M for the year ended Dec 31, 2025. In the last 12 months, Filana Therapeutics's executives and directors bought $997K of stock on the open market and sold none.

Chief executive, total pay$1.5MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$1.3MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$824KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.